Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Pipeline Analysis, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithms, and Key Players by DelveInsigh

As per DelveInsight's assessment, globally, about 18+ key pharma and biotech companies are working on 18+ pipeline drugs in the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types.

The emerging pipeline for PAD/ PVD majorly comprises cell therapies. Ixaka's REX-001, Hemostemix's ACP-01, Humacyte's Human Acellular Vessel (HAV), and Caladrius Bioscience's Honedra are the highlighted emerging therapies in the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) therapeutics market. The emerging therapies are in the late, middle, and early stages of development. Some of these emerging therapies are expected to enter the market in the near future. With the increasing prevalent cases of Peripheral Arterial Disease (PAD) and the expected launch of upcoming therapies, the Peripheral Arterial Disease therapeutics market may increase in the coming years.

"Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Peripheral Arterial Disease Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Peripheral Arterial Disease Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral Arterial Disease treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Peripheral Arterial Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Therapeutics Analysis
There are approx. 18+ key companies which are developing therapies for PAD/ PVD. Currently, Novo Nordisk is leading the therapeutics segment with its PAD/ PVD drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Include:
- NovoNordisk
- Takeda
- Mercator MedSystems, Inc.
- Beijing Northland Biotech. Co., Ltd.
- Ixaka Ltd
- Humacyte, Inc.
- CardioVascular BioTherapeutics
- Proteon Therapeutics
- ReNeuron Limited
- Alucent Biomedical
- Athersys
- ARCA biopharma
- Ambulero
- Venturis Therapeutics
- Hemostemix Inc.
- Caladrius Biosciences
- Reven Pharmaceuticals
- New Beta Innovation Limited
And many more

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Emerging Drugs Covered in the Report Include:
- Semaglutide: Novo Nordisk
- VM202: Helixmith
- ACP-01: Hemostemix Inc.
- REX-001: Ixaka Ltd (formerly known as Rexgenero)
- Honedra: Caladrius Biosciences
- Human Acellular Vessel (HAV): Humacyte, Inc.
- RJX (Rejuveinix): Reven Pharmaceuticals, Inc.
- YQ23: New Beta Innovation Limited
- Temsirolimus: Mercator MedSystems, Inc.
And many others

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Peripheral Arterial Disease Current Treatment Patterns
4. Peripheral Arterial Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Peripheral Arterial Disease Late Stage Products (Phase-III)
7. Peripheral Arterial Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Peripheral Arterial Disease Discontinued Products
13. Peripheral Arterial Disease Product Profiles
14. Peripheral Arterial Disease Key Companies
15. Peripheral Arterial Disease Key Products
16. Dormant and Discontinued Products
17. Peripheral Arterial Disease Unmet Needs
18. Peripheral Arterial Disease Future Perspectives
19. Peripheral Arterial Disease Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.